





and



where AB is an antibody.

19. The compound of any of claims 17-18, wherein said antibody AB is selected from trastuzumab, trastuzumab mutants, oregovomab, edrecolomab, cetuximab, a humanized monoclonal antibody to the vitronectin receptor ($\alpha v \beta 3$), alemtuzumab, anti HLA DR antibodies, 1311 Lym 1, anti HLA Dr10 antibodies, anti cd33 antibodies, anti cd22 antibodies, labetuzumab, bevacizumab, ibritumomab tiuxetan, ofatumumab, panitumumab, rituximab, tositumomab, ipilimumab, and gemtuzumab.

20. A pharmaceutical composition comprising a compound of any one of claims 1-18 or a pharmaceutically acceptable salt or solvate thereof, and pharmaceutically acceptable excipient.

21. Use of a therapeutically effective amount of a compound of any one of claims 1-18 or a pharmaceutical composition of claim 19 in the manufacture of a medicament for the treatment of cancer.

22. The use of claim 21, wherein said cancer is bladder cancer, breast cancer,

cervical cancer, colon cancer, endometrial cancer, kidney cancer, lung cancer, esophageal cancer, ovarian cancer, prostate cancer, pancreatic cancer, skin cancer, stomach (gastric) cancer, testicular cancer, leukemias and lymphomas.